New radioactive therapy targets Hard-to-Treat colorectal cancer
Disease control
Not yet recruiting
This early-stage study tests a new drug called SNA028 in 20 people with advanced colorectal cancer that has gotten worse after standard treatments. The drug uses a two-step process to deliver radiation directly to cancer cells that have a specific marker (GPA33). The main goals a…
Phase: EARLY_PHASE1 • Sponsor: SmartNuclide Biopharma • Aim: Disease control
Last updated May 19, 2026 11:46 UTC